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Abstract Rationale: Latent inhibition (LI) describes a
process by which repeated pre-exposure of a stimulus
without any consequence retards the learning of subse-
quent conditioned associations with that stimulus. It is
well established that LI is impaired in rats and in humans
by injections of the indirect dopamine agonist amphet-
amine (AMPH), and that this disruption can be prevented
by co-administration of either the typical neuroleptic
haloperidol (HAL) or the atypical neuroleptic clozapine
(CLZ). Objectives: Most of what is known of the
pharmacology of LI is derived from studies using either
the conditioned emotional response or the conditioned
active avoidance paradigm. The goal of the present study
was to determine whether these results would generalize
to the conditioned taste aversion assay. Methods: We
tested whether AMPH (0.5 mg/kg) pretreatment would
disrupt LI of a conditioned aversion to sucrose, and if so,
which stage of the procedure is critical for mediating the
disruption; in addition, we tested whether HAL (0.2 mg/
kg) or CLZ (5.0 mg/kg) could restore such an expected LI
disruption. Results: We determined that AMPH disrupted
LI when it was injected before pre-exposure and prior to
conditioning, but not if the rats were injected before either
stage alone. When HAL or CLZ was given 40 min before
AMPH (before both pre-exposure and conditioning), it
blocked LI disruption. Conclusion: These results are in
line with the pharmacology of LI as derived from other
conditioning paradigms. We conclude that the pharma-
cological regulation of LI in the CTA paradigm is similar
to what has been observed previously in the conditioned
emotional response and the conditioned active avoidance
paradigms.
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Introduction
Latent inhibition (LI) is the phenomenon, occurring in a
variety of species including humans and rats, whereby
repeated unreinforced stimulus presentation retards sub-
sequent conditioning to a stimulus (Lubow 1989). LI is
believed by many investigators to be the product of
learning to ignore irrelevant stimuli and, consequently, LI
has been linked to the selectivity of attentional processing
(Mackintosh 1975, Lubow et al. 1981, Lubow 1989).
Disrupted LI in the rat is considered an animal model of
cognitive/attentional deficits associated with schizophre-
nia, since it has been shown that acutely psychotic
schizophrenic patients show both reduced LI and atten-
tional deficits. However, LI is normalized during later
episodes of this chronic disorder, possibly due to the
effects of neuroleptic treatment (Baruch et al. 1988; Gray
NS et al 1992a, 1995).
The pharmacology of LI in non-human subjects has
been investigated using aversively-motivated LI proce-
dures such as conditioned emotional response (CER),
conditioned avoidance response (CAR), conditioned taste
aversion (CTA), conditioned eyeblink, and conditioned
freezing. LI can also be measured in appetitively moti-
vated and discrimination learning procedures, but there
has been only sporadic use of these methods (reviewed in
Moser et al. 2000). In the CTA paradigm, a novel taste
(CS, e.g. sucrose) is associated with illness induced by
lithium chloride (LiCl, US), thereby reducing subsequent
sucrose preference during test. LI is demonstrated when
animals pre-exposed (PE group) to the sucrose CS prior to
CS-US pairing in the conditioning session show less
sucrose aversion during the test session compared to non-
pre-exposed (NPE group) animals. In comparison to CER
and CAR procedures, only one CS-US pairing is neces-
sary for strong conditioning and only a single pre-
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exposure to the CS induces robust LI in the CTA test
(Russig et al., unpublished observation).
In animals and humans, the indirect dopamine agonist
amphetamine (AMPH) disrupts LI; conversely, neurolep-
tic drugs with dopamine receptor antagonist activity, such
as clozapine (CLZ) or haloperidol (HAL), can restore
AMPH-induced LI disruption and enhance LI when given
alone (Thornton et al. 1996; Kumari et al. 1999; Moser et
al. 2000; Weiner 2000; Russig et al. 2002). A range of
low doses of AMPH disrupt LI in CER (see Moser et al.
2000 for review) and CAR paradigms (Solomon et al.
1981; Weiner et al. 1988; Bakshi et al. 1995; De Oliveira
Mora et al. 1999). Similarly, most of our knowledge about
the capacity of compounds to reverse AMPH-induced
disruption of LI is based on findings in the CER
paradigm, with the exception of two studies which used
CAR to show that chlorpromazine, CLZ and HAL are
able to restore LI disruptions (Solomon et al. 1981, Russig
et al. 2002). Ellenbroek et al. (1997) showed in rats that
0.25 and 0.5 mg/kg AMPH disrupted LI in a CTA
paradigm. However, the ability of antipsychotic drugs
such as HAL or CLZ to either restore disrupted LI or
enhance normal LI has not yet been demonstrated in the
CTA paradigm.
For both AMPH and neuroleptic effects on LI, the
timing of drug administration is of critical importance in
determining whether a drug effect is seen. In a typical
experimental LI protocol in CER, the pre-exposure,
conditioning and test sessions are carried out in separate
sessions 24 h apart. When the experiment is conducted in
this manner, AMPH must be administered before both
pre-exposure and conditioning to disrupt LI (Weiner et al.
1984, 1988). However, a single administration of AMPH
has been found sufficient to disrupt LI in humans and in
rats if the pre-exposed CS duration was dramatically
enhanced or the pre-exposure and conditioning phases
were run in the same session (Gray NS et al. 1992b;
Moran et al. 1996; Thornton et al. 1996; McAllister
1997). Based on these and other data, it has been argued
that for AMPH to disrupt LI, it is actually the condition-
ing stage that is critical (Gray JA et al. 1995; Weiner and
Feldon 1997). In the CTA paradigm, it was shown that
AMPH disrupted LI when it was given before each of 3
pre-exposure days and the conditioning stage 24 h later
(Ellenbroek et al. 1997). Thus, it remains an open
question before which stage animals must be treated with
AMPH in order to disrupt LI in the CTA paradigm. In
contrast to the controversy over the relative importance of
different experimental stages to AMPH-induced LI dis-
ruption, there is consistent evidence that the critical time
for CLZ- or HAL-induced effects on LI is the condition-
ing stage. The effectiveness of these drugs in LI
facilitation or reversal of AMPH-induced LI disruption
was not altered by an additional injection before pre-
exposure (Peters and Joseph 1993; Weiner 2000; Russig
et al. 2002; Trimble et al. 2002).
For LI disruption in CER and CAR, the nucleus
accumbens has been suggested to be the critical structure
(Weiner and Feldon 1997; Murphy et al. 2000; Weiner
2000). However, recent experiments measuring c-Fos and
employing intracerebral AMPH infusions have suggested
that the striatum rather than the nucleus accumbens is the
critical structure for LI disruption in CTA (Ellenbroek et
al. 1997; Turgeon and Reichstein 2002). The same
investigation methods used in a CER paradigm suggest
a critical role of the nucleus accumbens rather than the
striatum for disrupted LI (Solomon and Staton 1982;
Sotty et al. 1996; Gray JA et al. 1997). With these
differences in mind, very little is known about possible
differences in the pharmacology of LI in CTA compared
to other behavioral tests. An important step to address this
issue is to investigate effects of AMPH, HAL and CLZ in
this paradigm.
Therefore, we tested in the present study if the effects
of AMPH, HAL and CLZ in CTA are comparable with
the pharmacology of LI observed in other paradigms. We
expected in experiment 1 that using a CTA procedure in
which a 24-h delay took place between pre-exposure,
conditioning and test sessions, LI would be disrupted if
0.5 mg/kg AMPH was administered 5 min before both the
pre-exposure and conditioning sessions. We also antici-
pated that this effect of LI disruption should not occur if
AMPH was administered either only before pre-exposure
or only before conditioning. In addition, we expected that
administration of 0.2 mg/kg HAL or 5.0 mg/kg CLZ prior
to AMPH before both pre-exposure and conditioning
would block the AMPH-induced LI disruption.
Material and methods
Animals
Male Wistar rats (Zur: WIST [HanIbm]; 250–350 g) obtained from
our in-house specific-pathogen-free (SPF) breeding facility were
used as subjects in these experiments. During the experiments, the
animals were housed individually in Macrolon type III cages
(482720 cm) under a reversed light-dark cycle (lights on 1800–
0600 hours) in a temperature (21€1C) and humidity (55€5%)
controlled animal facility. Food (Kliba 3430, Klibamhlen,
Kaiseraugst CH) was available ad libitum in the home cages. All
experiments were carried out between 8.00 a.m. and 1.00 p.m.
during the dark phase of the light-dark cycle. All procedures were
in agreement with Swiss Cantonal Veterinary Office regulations for
animal experimentation.
Drugs
d-Amphetamine sulfate (Sigma Chemical Company, St Louis,
USA) was dissolved in a 0.9% NaCl solution to obtain the dosage
of 0.5 mg/kg amphetamine (calculated as the salt). Vehicle-treated
groups received 0.9% NaCl solution. Haloperidol (HAL; Janssen-
Cilag, Baar, Switzerland) was prepared from 5 mg ampoules, in
which the drug is present in 1 ml of vehicle solution containing
6 mg lactic acid. This solution was subsequently diluted with saline
to obtain the required concentration of 0.2 mg/kg (final pH of 5.5).
Clozapine (CLZ; Novartis, Switzerland) was first dissolved in
0.1 N HCL in 0.9% saline solution and then neutralized to pH 5.5
with Na2CO3 in a final concentration of 5.0 mg/kg. Vehicle-treated
animals were administered either HAL vehicle (0.9% saline/lactic
acid, pH 5.5) or CLZ vehicle (0.1 N HCL/0.9% saline, pH 5.5). All
solutions were freshly prepared and administered intraperitoneally
in a volume of 1 ml/kg. Lithium chloride (LiCl, Sigma Chemical
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Company, St Louis, Mo. USA; 0.14 M) was dissolved in 0.9%
NaCl and administered in a volume of 1.5% body weight.
CTA apparatus
Before each session animals were transferred from the home cage
to a CTA test cage. The test cages were Macrolon cages
(42.526.615.0 cm) designed in such a way that two drinking
bottles could be attached and the spouts inserted through two holes
in the anterior part of the cage. The water and sucrose intake of
each animal were recorded by measuring the weight of the drinking
bottles before and after each drinking session.
CTA procedure
Prior to the beginning of each experiment, animals were handled
for 5 min each on 3 consecutive days and water deprived for the
following 8 days. During the first 3 days of water deprivation,
animals had access to water in the home cage for 1 h beginning at a
time between 9.00 and 10.00 a.m. On the following 2 days, animals
were exposed to the CTA test cages for 30 min where water was
given. On the next day, the pre-exposure session with one drinking
bottle was conducted in which animals were given either water
(non-pre-exposed, NPE) or 5% sucrose solution (pre-exposed, PE)
for 30 min in the test cages. Up to this stage, the drinking bottles
were switched once per exposure between the two holes in the test
cages to avoid the development of preference for one hole over the
other. On the next day, all animals experienced a conditioning
session in which they were given access to 5% sucrose solution for
15 min immediately followed by an injection of lithium chloride
(LiCl, 0.14 M, 1.5% of body weight) and were placed back in the
home cage. During the next day, all animals were placed in the
CTA cages and were given access to both 5% sucrose solution and
water presented in two different bottles for 30 min at the same time
(test session). Conditioned taste aversion was assessed by calcu-
lating the percent sucrose consumed (ml sucrose consumed100/ml
sucrose consumed+ml water consumed) on the test day. LI was
assessed by comparing the degree of taste aversion between PE and
NPE animals within each treatment group.
Experiment 1: effects of 0.5 mg/kg amphetamine injected
before different experimental stages on the development
of latent inhibition in a conditioned taste aversion paradigm
A dose of 0.5 mg/kg AMPH or saline was injected 5 min before the
pre-exposure session, conditioning session, or before both sessions.
A saline injection was given before all sessions without the AMPH
treatment. The test session was conducted in a drug-free state. The
dose of 0.5 mg/kg AMPH was selected because disrupted LI has
been shown with this dose in the CER, passive avoidance and CTA
paradigms (Killcross et al. 1994; Ellenbroek et al. 1997; De
Oliveira Mora et al. 1999).
We excluded from analysis 12 animals that consumed less than
1.0 ml of solution during the pre-exposure or conditioning session.
The final number of animals in each of the eight conditions was:
SAL/SAL NPE, n=10; SAL/SAL PE, n=10; AMPH/SAL NPE,
n=8; AMPH/SAL PE, n=9; SAL/AMPH NPE, n=8; SAL/AMPH
PE, n=8; AMPH/AMPH NPE, n=7; AMPH/AMPH PE, n=8.
Experiment 2: effects of 0.2 mg/kg haloperidol on 0.5 mg/kg
amphetamine-induced disruption of latent inhibition
of conditioned taste aversion
Experiment 1 clearly showed that LI was reduced only if AMPH
was given before both the pre-exposure and the conditioning
sessions in the CTA paradigm. In experiment 2, either 0.2 mg/kg
HAL or vehicle was injected 40 min prior to injection of either
0.5 mg/kg AMPH or saline, 5 min prior to the beginning of both the
pre-exposure and conditioning sessions. During the test session all
the animals were drug-free. The dose of 0.2 mg/kg HAL was
selected because dosages between 0.1 mg/kg and 0.5 mg/kg IP are
effective in the reversal of AMPH (1.0 and 1.5 mg/kg) induced
disruption of LI (Warburton et al. 1994; Millan et al. 1998).
We excluded from the analyses five animals that consumed less
then 1.0 ml during the pre-exposure or the conditioning session.
The final number of animals in each of the eight conditions was:
SAL/SAL NPE, n=10; SAL/SAL PE, n=10; HAL/SAL NPE, n=9;
HAL/SAL PE, n=9; SAL/AMPH NPE, n=9; SAL/AMPH PE, n=9;
HAL/AMPH NPE, n=10; HAL/AMPH PE, n=9.
Experiment 3: effects of 5.0 mg/kg clozapine on 0.5 mg/kg
amphetamine-induced disruption of latent inhibition
of conditioned taste aversion
The experimental procedures were similar to those of experiment 2,
but instead of the typical antipsychotic drug HAL, the appropriate
treatment groups received 5.0 mg/kg of the typical antipsychotic
drug CLZ. The dosage of 5.0 mg/kg CLZ was selected because
dosages between 2.0 mg/kg and 10.0 mg/kg IP are effective in the
reversal of AMPH (1.0 and 1.5 mg/kg) induced disruption of LI
measured in a CER paradigm (Moran et al. 1996; Weiner et al.
1996; Millan et al. 1998).
We excluded from the analyses 14 animals that consumed less
then 1.0 ml during the pre-exposure or the conditioning session.
The final number of animals in each of the eight conditions was:
SAL/SAL NPE, n=9; SAL/SAL PE, n=8; CLZ/SAL NPE, n=7;
CLZ/SAL PE, n=9; SAL/AMPH NPE, n=8; SAL/AMPH PE, n=9;
CLZ/AMPH NPE, n=8; CLZ/AMPH PE, n=8.
Statistics
Statistical analysis of the data was conducted using StatView
version 5.0.1. For all measurements in experiment 1, we used a
222 ANOVA design with the three between-subjects factors of
drug treatment before pre-exposure (drug PE: SAL or AMPH), drug
treatment before conditioning (drug COND: SAL or AMPH) and
pre-exposure (PE or NPE). All measurements in experiments 2 and
3 were analyzed with 222 ANOVA designs with three between-
subjects factors of drug treatment (SAL, AMPH), neuroleptic
treatment (SAL, HAL or CLZ) and pre-exposure (NPE, PE).
Whenever an interaction between two main factors was significant,
the post-hoc Fisher’s protected least significant difference test was
applied.
Results
Experiment 1: effects of 0.5 mg/kg amphetamine injected
before different experimental stages on the development
of latent inhibition in a conditioned taste aversion
paradigm
Pre-exposure session
Animals with access to sucrose (PE groups) consumed
more solution than animals that had access only to water,
as reflected by a main effect of pre-exposure
[F(1,60)=7.19, P<0.01; see Fig. 1A]. The analysis also
revealed a significant drug PEdrug CONDpre-exposure
interaction [F(1,60)=4.219, P<0.05]. A post hoc analysis
of this interaction revealed that the SAL/AMPH PE group
drank more than the other groups, effects that were
significant versus the SAL/AMPH NPE group
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(P=0.0001), AMPH/SAL NPE group (P=0.0001) and
AMPH/AMPH PE group (P=0.0003). No other significant
main effects or interactions were found.
Conditioning session
Rats that had access to sucrose during the pre-exposure
stage (PE groups) exhibited overall more sucrose intake
compared to the NPE groups, as reflected by a significant
main effect of pre-exposure [F(1,60)=4.785, P<0.05;
Fig. 1B]. The analyses also revealed a significant main
effect of drug during conditioning [F(1,60)=29.916,
P<0.0001], reflecting a reduced fluid intake for animals
treated with AMPH before conditioning in comparison to
SAL injected controls. This effect was more pronounced
in animals that received AMPH also before pre-exposure,
as reflected by a drug PEdrug COND interaction
[F(1,60)=4.387, P<0.05]. There were no other significant
main effects or interactions.
Test session
Overall expression of LI, as reflected by higher percent
sucrose intake in PE compared with NPE animals, was
confirmed by a significant main effect of pre-exposure
[F(1,60)=13.563, P<0.001, Fig. 1C]. However, the LI
effect was not similar in all the treatment groups, as
reflected by a significant drug PEpre-exposure interac-
tion [F(1,60)=5.681, P<0.03] and drug CONDpre-
exposure interaction [F(1,60)=7.161, P<0.01] and signif-
icant drug PEdrug CONDpre-exposure interaction
[F(1,60)=4.314, P<0.05]. Post hoc analyses revealed
significantly more percent sucrose intake in PE compared
to NPE animals (i.e. LI) in the groups that were treated
with AMPH either only before pre-exposure (AMPH/
SAL, NPE versus PE P=0.0046), only before conditioning
(SAL/AMPH, NPE versus PE P=0.0094) and in the
control group (SAL/SAL, NPE versus PE, P<0.0001). No
significant LI was obtained in animals treated with an
AMPH injection both before pre-exposure and condition-
ing (AMPH/AMPH, group NPE versus PE, P=0.2747).
Comparing only the NPE groups of the different drug
conditions AMPH/AMPH animals exhibited more percent
sucrose intake than the AMPH/SAL NPE animals
(P=0.0259), but did not differ significantly (P>0.353)
from the other NPE groups. Within the PE groups, the
AMPH/AMPH animals consumed significantly less per-
cent sucrose compared to the SAL/AMPH (P=0.0285)
and the SAL/SAL (P=0.0068) groups, but did not differ
significantly from the AMPH/SAL group (P=0.148).
There was no significant main effect or interaction in
the measure of total liquid consumption (water+sucrose,
Fig. 1D).
Experiment 2: effects of 0.2 mg/kg haloperidol on 0.5 mg/
kg amphetamine-induced disruption of latent inhibition of
conditioned taste aversion
Pre-exposure session
Animals with access to sucrose (PE groups) consumed
more solution compared to the NPE groups that drank
water, as reflected by a highly significant main effect of
pre-exposure [F(1,67)=17.936, P<0.0001, Fig. 2A]. A
significant drug treatmentpre-exposure interaction
[F(1,67)=4.903, P<0.05] reflected that this effect was
more pronounced in the SAL-treated compared to the
AMPH-treated animals.
Conditioning session
During the conditioning session, all groups exhibited
similar sucrose intake and there were no significant main
effects or interactions including the factors of pre-
exposure, drug treatment or neuroleptic treatment
(Fig. 2B).
Fig. 1A–D Effects of amphetamine (AMPH) or saline (SAL)
administration before different stages of an experiment measuring
latent inhibition of conditioned taste aversion. A Liquid consump-
tion (in ml) during the pre-exposure session for sucrose pre-
exposed (PE) and non-pre-exposed (NPE) animals. NPE animals
had access to water while PE animals received sucrose. B Sucrose
consumption (in ml) during the conditioning session. C Percent
sucrose intake during the test session during which all animals had
access to water and sucrose. D Total liquid consumption (in ml,
sucrose+water) during the test session. The groups were injected
with saline (SAL-SAL) or amphetamine (AMPH-AMPH) before
both the pre-exposure and the conditioning sessions, with amphet-
amine before pre-exposure and saline before conditioning (AMPH-
SAL) or with saline before pre-exposure and amphetamine before
conditioning (SAL-AMPH). Values are means€SEM
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Test session
The presence of LI, as indicated by higher percent sucrose
intake in PE compared with NPE animals, was supported
by a highly significant main effect of pre-exposure
[F(1,67)=29.982, P<0.0001; Fig. 2C]. AMPH-treated
animals showed lower percent sucrose intake on the test
day compared to the controls and this effect was mainly
due to a reduction in the SAL/AMPH PE animals, as
reflected by a significant main effect of drug treatment
[F(1,67)=15.208, P<0.0005] and a significant drug treat-
mentpre-exposure interaction [F(1,67)=5.274, P<0.03].
HAL treated rats showed enhanced percent sucrose intake
compared to controls (main effect of neuroleptic treat-
ment [F(1,67)=7.762, P<0.01]. Fishers post hoc compar-
isons between NPE and PE animals for all conditions
revealed that LI was not present in AMPH treated animals
and that the disruption was antagonized by pretreatment
with HAL (NPE versus PE: SAL/SAL P=0.0018, HAL/
SAL P=0.0002, SAL/AMPH P=0.7247, HAL/AMPH
P=0.0048). A comparison of only the PE groups showed
that the SAL/AMPH group showed reduced % sucrose
intake compared to the other three PE groups (all
P<0.0001) without a significant effect between these
three groups. The NPE groups did not differ between the
different treatment conditions in percent sucrose intake
during the test session. In the analysis of overall
water+sucrose intake, PE animals drank more than NPE
animals, as reflected by a significant main effect of pre-
exposure [F(1,67)=8.136, P<0.01], reflecting their in-
creased sucrose intake (Fig. 2D). There were no signif-
icant interactions of total fluid intake with drug or
neuroleptic treatment.
Experiment 3: effects of 5.0 mg/kg clozapine
on 0.5 mg/kg amphetamine-induced disruption
of latent inhibition of conditioned taste aversion
Pre-exposure session
Similarly to experiments 1 and 2, animals with access to
sucrose (PE groups) consumed more solution compared to
the NPE groups that drank water, as reflected by a highly
significant main effect of pre-exposure [F(1,58)=21.497,
P<0.0001, Fig. 3A]. In addition, AMPH pretreated
animals consumed less solution during the 30-min pre-
exposure session compared to SAL pretreated animals
irrespective of the neuroleptic pretreatment. This effect
was reflected by a significant main effect of drug
treatment [F(1,58)=4.625, P<0.05]. There were no addi-
tional significant main effects or interactions.
Fig. 3A–D Effects of amphetamine (AMPH), clozapine (CLZ) or
saline (SAL) administration before pre-exposure and conditioning
sessions in an experiment measuring latent inhibition of condi-
tioned taste aversion. A Liquid consumption (in ml) during the pre-
exposure session for sucrose pre-exposed (PE) and non-pre-
exposed (NPE) animals. NPE animals had access to water while
PE animals received sucrose. B Sucrose consumption (in ml) during
the conditioning session. C Percent sucrose intake during the test
session during which all animals had access to water and sucrose. D
Total liquid consumption (in ml, sucrose+water) during the test
session. Animals were injected with saline (SAL-SAL), amphet-
amine (SAL-AMPH), clozapine (CLZ-SAL) or amphetamine and
clozapine (CLZ-AMPH) before both pre-exposure and test sessions.
Values are means€SEM
Fig. 2A–D Effects of amphetamine (AMPH), haloperidol (HAL) or
saline (SAL) administration before pre-exposure and conditioning
sessions in an experiment measuring latent inhibition of condi-
tioned taste aversion. A Liquid consumption (in ml) during the pre-
exposure session for sucrose pre-exposed (PE) and non-pre-
exposed (NPE) animals. NPE animals had access to water while
PE animals received sucrose. B Sucrose consumption (in ml) during
the conditioning session. C Percent sucrose intake during the test
session during which all animals had access to water and sucrose. D
Total liquid consumption (in ml, sucrose+water) during the test
session. Animals were injected with saline (SAL-SAL), amphet-
amine (SAL-AMPH), haloperidol (HAL-SAL) or amphetamine and
haloperidol (HAL-AMPH) before both pre-exposure and test
sessions. Values are means€SEM
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Conditioning session
During the conditioning session, animals treated with
AMPH consumed less sucrose solution compared to
animals that received SAL [F(1,58)=6.568, P<0.05;
Fig.3B]. A significant main effect of neuroleptic pretreat-
ment [F(1,58)=4.39, P<0.05] reflected the fact that
animals treated with CLZ showed reduced sucrose
consumption during the conditioning session compared
to vehicle treated animals. Rats that had access to sucrose
during the pre-exposure stage (PE groups) exhibited
overall more sucrose intake compared to the NPE groups,
as reflected by a significant main effect of pre-exposure
[F(1,58)=4.733, P<0.05]. There were no significant
interactions involving any of these three between-subjects
factors.
Test session
The overall presence of LI was indicated by the fact that
PE groups showed increased percent sucrose intake
compared to NPE groups, as reflected by a highly
significant main effect of pre-exposure [F(1,58)=43.391,
P<0.0001; Fig. 3C]. Animals treated with AMPH before
both the pre-exposure and the conditioning session
showed reduced percent sucrose intake during the test
session compared to the SAL-pretreated animals, as
reflected by a significant main effect of drug treatment
[F(1,58)=4.972, P<0.05]. On the other hand, animals
previously treated with CLZ showed enhanced percent
sucrose intake compared to animals treated with vehicle
and this effect was more pronounced in the PE groups
compared to the NPE groups. These effects were
supported by a significant main effect of neuroleptic
treatment [F(1,58)=11.162, P<0.005] and a significant
neuroleptic treatmentpre-exposure interaction
[F(1,58)=7.748, P<0.01]. Fisher’s post hoc comparisons
between NPE and PE animals within all four conditions
revealed that LI was not present in AMPH treated animals
and that the disruption was antagonized by pretreatment
with CLZ (NPE versus PE: SAL/SAL P=0.0158, CLZ/
SAL P=0.0008, SAL/AMPH P=0.358, CLZ/AMPH
P=0.0001). A post hoc comparison of only the PE groups
for all conditions revealed a significantly reduced percent
sucrose intake in the SAL/AMPH group compared to the
other three groups (all P<0.05). In addition, CLZ/SAL PE
animals exhibited enhanced percent sucrose intake com-
pared to rats in the SAL/SAL PE condition (P=0.0115).
Similar Fisher’s post hoc comparisons restricted to only
the NPE groups of all four conditions did not reveal any
significant outcome. The analysis of overall sucrose+wa-
ter intake during the test session revealed a significant
main effect of neuroleptic treatment [F(1,58)=6.027,
P<0.05], reflecting that animals previously treated with
CLZ showed slightly enhanced solution intake compared
to SAL treated animals (Fig. 3D). No other significant
main effects or interactions were obtained in the analysis
of overall solution intake during the test session.
Discussion
Experiment 1 showed that LI was disrupted in the CTA
paradigm if an acute injection of 0.5 mg/kg AMPH was
given before both the pre-exposure and the conditioning
sessions. Animals that received AMPH either only before
pre-exposure or only before conditioning exhibited nor-
mal LI. In experiments 2 and 3, administration of HAL or
CLZ 40 min before the AMPH administration on both the
pre-exposure and conditioning days blocked the AMPH-
induced LI disruption.
During the pre-exposure phase in all three experi-
ments, animals that had access to sucrose (PE groups)
consumed more than animals that had only water to drink.
These findings indicate that sucrose had more rewarding
properties than water in general and was therefore more
readily consumed, replicating the findings of Ellenbroek
et al. (1997). During the conditioning session of exper-
iments 1 and 3 but not 2, animals treated with AMPH
before conditioning showed reduced sucrose intake com-
pared to SAL-injected animals, thereby replicating find-
ings of an AMPH-induced reduction of drinking (Foltin et
al. 1983; Shepard 1988; Velazquez-Martinez et al. 1995).
However, since the critical measure for LI is the
difference between NPE and PE animals within a
treatment group, and both were similarly influenced by
AMPH we do not believe that these small and non-
specific effects confounded our results concerning LI in
CTA.
In experiment 1, we clearly showed that LI in CTA can
be disrupted by AMPH only if the drug is administered
before both pre-exposure and conditioning. A single
injection given only before pre-exposure or conditioning
left LI intact. These results are consistent with findings
previously reported in the CER procedure (Weiner et al.
1984, 1988). Thus, in order to disrupt LI in CER or CTA
protocols in which pre-exposure, conditioning and test
sessions are separated by 24-h intervals, it seems to be
necessary to administer AMPH before both pre-exposure
and conditioning. It has been suggested that processes of
sensitization might be required for AMPH-induced LI
disruption in experimental designs in which two injec-
tions must be given (Weiner et al 1988; Gray NS et al.
1995). We are currently examining whether, similar to
CER, sensitization processes in CTA might also be
responsible for AMPH-induced LI disruption.
The AMPH-induced LI disruption in all experiments
was due to a significant reduction of percent sucrose
intake in the AMPH/AMPH PE group compared to the
control PE animals. However, in experiment 1 but not 2
or 3, an additional non-significant increase in percent
sucrose intake was observed in AMPH/AMPH NPE
animals. It has been suggested that in order to obtain
clearly interpretable results, drugs inducing LI disruption
should selectively increase retarded CS-US conditioning
in the treated PE group to levels expressed by the NPE
group without altering conditioning in the NPE group
itself (Lubow 1989; Weiner and Feldon 1997; Weiner
2000). It is unclear why in the first experiment the
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AMPH/AMPH NPE group showed somewhat increased
percent sucrose intake; nevertheless, percent sucrose
intake in the AMPH/AMPH NPE group did not differ
significantly from that in the SAL/SAL NPE group. Given
that elevated percent sucrose intake in the AMPH/AMPH
NPE group was seen in only one of the three experiments,
we believe that the effect was due to higher variability
from random sampling error. It should be noted, more-
over, that in both experiments, the animals belonging to
the PE condition which was treated with AMPH before
pre-exposure and conditioning showed less percent
sucrose consumption compared with all other PE groups.
Based on the results obtained in experiment 1, we
investigated the capacity of HAL and CLZ injected
45 min before pre-exposure and conditioning to block
AMPH induced LI disruption in the CTA paradigm. To
our knowledge, there are no published studies in the LI
literature in which antipsychotic drugs and their influence
on LI have been investigated in the CTA paradigm. In
addition, there are only a few studies investigating
antipsychotic compounds in LI procedures other than
CER (Solomon et al. 1981, Weiner et al. 1987, Loskutova
et al. 1990, Russig et al. 2002). Experiments 2 and 3
showed that HAL or CLZ injected before pre-exposure
and conditioning blocked AMPH-induced LI disruption in
a CTA paradigm. The disruption was clearly due to
decreased percent sucrose intake in the SAL/AMPH PE
group and HAL and CLZ antagonized this effect by
increasing the percent sucrose intake of the HAL/AMPH
and CLZ/AMPH PE groups to levels exhibited by the
SAL/SAL PE groups. Interestingly, HAL/SAL animals
exhibited slightly enhanced percent sucrose intake com-
pared to the SAL/SAL group. This tendency was present
in both the PE and the NPE groups but was most obvious
in the PE groups. Nevertheless, the magnitude of LI was
similar in the SAL/SAL and the HAL/SAL conditions,
indicating that LI was not augmented by HAL in this
experiment. In contrast, the results of experiment 3
suggest that CLZ induced enhancement of LI can be
observed also in the CTA paradigm. Within experiment 3,
CLZ/SAL PE animals exhibited significantly more per-
cent sucrose intake compared to the SAL/SAL PE group
and this effect of CLZ cannot be interpreted as general
since the CLZ/SAL NPE animals did not significantly
differ from the SAL/SAL NPE group. Enhanced LI by
HAL might also be detectable in future experiments using
different dosages, or if the procedural parameters were
manipulated in such a way that LI in controls was less
pronounced, given indications that neuroleptic-induced LI
enhancement is best seen on a background of no LI in the
controls (Weiner and Feldon 1997; Moser et al. 2000). LI
in the controls could be reduced by shortening the
duration of the pre-exposure session, restricting sucrose
intake during pre-exposure, or reducing the dose of LiCL
and thereby reducing the strength of the CS-US associ-
ation (Weiner 2000). Finally, the LI effects of experi-
ments 2 and 3 cannot be due simply to an effect of the
various treatments on drinking behavior per se, because
drinking was not influenced by either the AMPH or the
HAL treatment during the test session. Moreover,
although CLZ enhanced the total solution intake during
the test session, the analysis did not reveal any statisti-
cally significant interactions with the factors of drug
treatment or pre-exposure, suggesting that this effect
cannot be responsible for the observed effects on LI in the
different drug conditions.
Theoretically, there are some potential problems of
interpretation in using CTA as a paradigm to investigate
LI. AMPH effects on LI in CTA might be confounded by
the fact that AMPH itself can induce conditioned taste
aversion (Miller and Miller 1983; Greenshaw and Dourish
1984; Goudie and Newton 1985). In our experiments 1
and 2, there were no significant differences in sucrose
intake between the pre-exposure and the conditioning
sessions in animals that received AMPH before sucrose
pre-exposure (AMPH PE group). Consequently, it is very
unlikely that our low dose of AMPH induced an
independently conditioned taste aversion in these rats.
Another criticism regarding measurements of LI in CTA
is that pre-exposure to the sucrose CS in these experi-
ments is not really without a consequence because the CS
reduces thirst in water-deprived animals and provides a
rewarding taste. Therefore, it could be argued that PE
animals do not really learn to ignore the CS; in fact, the
opposite is the case—they learn to appreciate the sweet
solution, a fact that perhaps strengthens the LI effect
(Moser et al. 2000). Nevertheless, LI was disrupted by a
very low dose of AMPH in the present experiment. It is
interesting that the pharmacology of AMPH, HAL and
CLZ in the LI CTA paradigm is very similar to results
obtained in paradigms not confounded by these theoret-
ical criticisms, such as the CAR and CER procedures.
Taken together, our results show that 1) LI is disrupted
in the CTA paradigm if AMPH is administered before
both pre-exposure and conditioning and 2) this disruption
can be blocked by HAL and CLZ. These results indicate
that the pharmacology of LI regulation by dopamine
agonists and antagonists is similar in the CTA paradigm
to that of other tests such as CAR and CER.
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